Search clinical trials for: Sindillimab

Total 413 results

Peking Union Medical College Hospital
Henan Cancer Hospital; Qilu Hospital of Shandong University; Beijing Tongren... and other collaborators

Recruiting

Phase II Study of Orelabrutinib Combined With PD-1 Inhibitor in Relapsed/Refractory Primary Central Nervous System Lymphoma

Primary Central Nervous System Lymphoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Study Evaluating the Safety, Tolerability, and Initial Efficacy of IBI110 in Subjects With Advanced Malignant Tumors

Advanced Malignancies

China
Shanghai Changzheng Hospital

Completed

Anlotinib Plus Sintilimab as First-line Treatment for Patients With Advanced Colorectal Cancer (APICAL-CRC)

Colorectal Cancer | Immunotherapy | Sintilimab | First-line Treatment | Anlotinib | Chemo-free Therapy

China
AIPING ZHOU

Unknown

Phase II Trial of Fruquintinib With Sintilimab in Treating Selected Refractory Metastatic Colorectal Cancer Patients

Colorectal Cancer

China
Shanghai Zhongshan Hospital
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

Combined Locoregional Treatment With Immunotherapy for Unresectable HCC.

Hepatic Carcinoma

China
Tongji Hospital

Not yet recruiting

Postoperative Adjuvant Sintilimab in Hepatocellular Carcinoma With Microvascular Invasion

Hepatocellular Carcinoma

China
The First Affiliated Hospital of Xiamen University

Not yet recruiting

Stereotactic Ablation Radiotherapy Combined With Sintilimab in Early Inoperable Synchronous Multiple Primary Lung Cancer

Multiple Primary Lung Cancer
Sun Yat-sen University

Completed

Combined Treatment of Sintilimab, Peg-aspargase Plus Anlotinib in NK/T Cell Lymphoma

Radiotherapy | Sintilimab | Anlotinib | Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type | Early Stage | Peg-aspargase | Phase Two | Open

China
Tianjin Medical University Cancer Institute and...

Recruiting

Multi-cohort Study of Surufatinib Plus Sintilimab in Metastatic NEN and Pancreatic Carcinoma Who Failed Standard Chemotherapy

Pancreatic Carcinoma | Neuroendocrine Carcinoma | Neuroendocrine Tumor Grade 3

China
Zhejiang Cancer Hospital

Not yet recruiting

Eribulin Combined With Sintilimab as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Breast Cancer:A Multicenter, Single-arm,Phase II Clinical Trial

Metastatic Breast Cancer

China
Tianjin Medical University Second Hospital

Not yet recruiting

Sintilimab After Stereotactic Ablation Brachytherapy for Refractory Oligometastatic Non-Small Cell Lung Cancer

Lung Neoplasms | Oligometastasis
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Phase II Clinical Study to Assess the Efficacy and Safety of IBI310 or Placebo Combined With Sintilimab for Advanced Cervical Cancer Subjects Who Have Failed or Cannot Tolerate First-line or Above Platinum-based Chemotherapy

Advanced Cervical Cancer

China
First Hospital of Shijiazhuang City

Unknown

Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M Negative

Carcinoma | Non-small Cell Lung Cancer | Lung Neoplasm

China
Fujian Medical University Union Hospital

Not yet recruiting

Postoperative Immune Maintenance Therapy for Esophageal Squamous Cell Carcinoma After Radical Resection

Esophageal Squamous Cell Carcinoma Thoracic Stage II | Esophageal Squamous Cell Carcinoma Thoracic Stage III | Esophageal Squamous Cell Carcinoma Thoracic Stage IV

China
Taizhou Hospital

Recruiting

Adjuvant Chemotherapy and Anti-PD-1 Antibody in Patients With Stage IIIC2-IVB Cervical Cancer (CRTCP)

Cervical Cancer

China
Sichuan Cancer Hospital and Research Institute
Innovent Biologics, Inc.

Unknown

Sintilimab (IBI308) in the Neoadjuvant Treatment of Patients With Resectable II-IIIA NSCLC

Neoplasms | Respiratory Tract Diseases | Lung Diseases | Thoracic Neoplasms | Non-small-cell Lung Cancer
Fujian Haixi Pharmaceuticals Co., Ltd.

Recruiting

Assessment of the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors

Solid Tumor

China
Xin-Hua Xu

Recruiting

The Clinical Significance of Peripheral Blood T Lymphocyte PD-1 Expression and T Cell Subset Distribution.

Hepatocellular Carcinoma

China
Wuhan Union Hospital, China

Not yet recruiting

Study of Surufatinib Combined With Sintilimab and SCRT in Advanced Solid Tumors

Unresectable Advanced Solid Tumors | Biliary Tract Tumors, Gastric Cancer, Small Cell Lung Cancer

China
Peking University

Recruiting

Sintilimab Combined With IBI310 and Surufatinib for the Treatment of G3-NET and NEC

Neuroendocrine Neoplasm

China
Hua Li

Withdrawn

Radiofrequency Ablation in Combination With Lenvatinib and Sintilimab

Hepatocellular Carcinoma

China
Fudan University

Recruiting

The Combination of Immunotherapy and Stereotactic Ablative Radiotherapy in MSS Oligometastatic Colorectal Cancer

Colorectal Cancer

China
Zhongda Hospital

Recruiting

HAIC Combined With Donafenib and Sintilimab for Unresectable ICC

Cholangiocarcinoma

China
Shandong Cancer Hospital and Institute

Recruiting

Sintilimab Combined With Fruquintinib/Regorafenib ± Radiotherapy for Third-line Treatment of Advanced Metastatic Colorectal Cancer

Colorectal Cancer | Radiotherapy | Immunotherapy | Targeted Therapy

China
The First Affiliated Hospital of Zhengzhou University

Not yet recruiting

IBI110 Combined With Sintilimab in Second-line Advanced or Metastatic Esophageal Squamous Cell Carcinoma(ESCC)

Esophageal Squamous Cell Carcinoma (ESCC) | PD-1 Inhibitors

China
West China Hospital
Sichuan Provincial People's Hospital; The First People's Hospital of Ziyang; Chengdu... and other collaborators

Not yet recruiting

The Efficacy and Safety of Sintilimab in Combination With Multimodal Radiotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma
Tianjin Medical University Cancer Institute and...

Recruiting

Efficacy and Safety of Sintilimab Combined With Regorafenib and Cetuximab / Sintilimab Combined With Regorafenib in Posterior Line Therapy of Advanced Colorectal Cancer (Regosinti)

Sintilimab, Cetuximab, Regorafenib,Combine,mCRC

China
Shandong Cancer Hospital and Institute

Recruiting

Sintilimab Combined With Chemotherapy and Radiotherapy in Patients With Inoperable Pancreatic Cancer

Pancreas Cancer

China
jianming xu
NeoCura

Recruiting

A Safety and Efficacy Study of XH001 Combined With Sintilimab Injection in Advanced Solid Tumors

Solid Tumor

China
Shandong Cancer Hospital and Institute

Not yet recruiting

A Phase I Study of IBI325 in Patients With Advanced Solid Tumor

Solid Tumor

China
Sun Yat-sen University

Recruiting

A Phase II Clinical Study of Surufatinib Combined With Sintilimab in the Treatment of Advanced Gastric Cancer

Gastric Adenocarcinoma

China
Mian XI

Recruiting

Combination of Sintilimab and Stereotactic Body Radiotherapy in Hepatocellular Carcinoma (ISBRT01) (ISBRT01)

Hepatocellular Carcinoma

China
Hutchmed

Recruiting

: A Phase Ib/II Study To Evaluate Fruquintinib Monotherapy Or Plus Sintilimab In Advanced Solid Tumors

Advanced Solid Tumor

China
The First People's Hospital of Changzhou

Not yet recruiting

Regorafenib and Sintilimab in Combination With Electroacupuncture in MSS CRC

Colorectal Cancer Metastatic
Henan Cancer Hospital

Recruiting

Fruquintinib in Combination With Sintilimab and CAPEOX as First-line Treatment for G/GEJ Cancer

Metastatic Gastroesophageal Junction Adenocarcinoma

China
Peking Union Medical College Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.; Xinda Biopharmaceutical Group

Not yet recruiting

Sintilimab Combined With Anlotinib Therapy for Initially Unresectable Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Phase I Study of IBI325 in Patients With Advanced Solid Tumor

Solid Tumor

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-T-cell Immunoreceptor With Ig and ITIM Domains (TIGIT) Monoclonal Antibody Injection (IBI939) in Subjects With Advanced Malignant Tumors

Advanced Malignancies

China
Zhejiang Cancer Hospital

Completed

Sintilimab Combined With Anlotinib in Advanced NSCLC With EGFR Uncommon Mutations

Lung Cancer

China
Sun Yat-sen University

Recruiting

Neoadjuvant Immunochemotherapy in Locally Advanced Esophagogastric Junction Adenocarcinoma

Esophagogastric Junction Adenocarcinoma

China
Tang-Du Hospital

Completed

Sintilimab and Anlotinib Combined With Chemotherapy in Neoadjuvant Treatment of Resectable Esophageal Cancer

Sintilimab and Anlotinib in Combination With Chemotherapy

China
China Medical University, China
Shengjing Hospital; The People's Hospital of Liaoning Province; The First People... and other collaborators

Unknown

A Phase II Study of Anti-PD-1 Antibody, Sintilimab, as Second-line Therapy for Biomarker-selected Advanced or Metastatic NSCLC

Non-small Cell Lung Cancer

China
Hebei Medical University Fourth Hospital

Recruiting

Study of Anti-PD-1 Antibody Multimodal Combination as First-line Treatment on Time Window of Advanced Solid Tumor

Advanced Solid Tumor

China
The First Affiliated Hospital of Soochow University
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

Effectiveness of Neoadjuvant Chemotherapy Combined With PD-1 Monoclonal Antibody in the Treatment of Operable Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

Efficacy and Safety of IBI110 Single Agent and in Combination With Sintilimab in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma (r/r DLBCL)

DLBCL

China
Fudan University

Recruiting

SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC

NSCLC Stage IV

China
The First Hospital of Jilin University

Active, not recruiting

Neoadjuvant Immunotherapy Plus Chemotherapy for Potentially Resectable Stage IIIA/IIIB Non-Small Cell Lung Cancer (Neo-Pre-IC)

IIIA Stage Non-small Cell Lung Cancer

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study of IBI310 for the Treatment of Patients With Advanced Solid Tumors.

Advanced Solid Tumors

China
Henan Cancer Hospital

Unknown

Study of Sintlimab Maintenance Therapy in Patients With Extensive Small Cell Lung Cancer

Small Cell Lung Cancer | Chemotherapy | Adoptive Cellular Immunotherapy | Maintenance | Extensive Disease

China
Tianjin Medical University Cancer Institute and...

Recruiting

Clinical Study of Surufatinib Plus Sintilimab Combined With Chemotherapy in the Treatment of Advanced Gastric Neuroendocrine Carcinoma

Gastric Neuroendocrine Carcinoma

China

3

Subscribe